Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine
- 8 September 2008
- journal article
- review article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (10), 2967-2992
- https://doi.org/10.1185/03007990802381364
Abstract
Background: Topical formulations of non-steroidal anti-inflammatory drugs (NSAIDs), in particular diclofenac (DI), have become popular for treating various acute and chronic painful inflammatory conditions. Objective: To perform a literature review of (1) the use of topical NSAIDs; (2) the pharmaceutical, pharmacokinetic and pharmacodynamic properties of a medicated plaster (patch) containing diclofenac epolamine (DI-EP, Flector Tissugel, Flector patch*) compared with other formulations of topical NSAIDs; and (3) evaluation of the clinical findings from studies with this novel DI-EP patch. Outcomes: (1) Pharmacokinetic studies involved determination of DI from DI-EP and separately epolamine (EP) and the epoxide metabolite (N-oxide-EP) in laboratory animals and humans; the latter being the major metabolite in humans. About 2% of DI is absorbed by the skin in humans and is excreted in the urine. Maximum plasma concentrations of 17.4 ng/mL DI are reached at 5.4 hours (approximate steady state conditions); the plasma elimination half-time (t½) being 26.4 hours. Low systemic levels of DI and EP are produced from DI-EP. Pronounced accumulation of DI occurs in the muscle layers and in synovial fluids of arthritic patients; (2) No significant toxicity occurs from EP nor N-oxide-EP, while that of oral DI-EP was similar to that from DI; and (3) In acute musculoskeletal conditions (sprains, tendonitis and sports injuries) and osteoarthritis DI-EP patches control pain and signs of joint or physical injury compared with placebo controls by 3–5 days with almost complete pain relief at 14 days. DI-EP was shown to have equivalent therapeutic effect to another DI diethylammonium gel formulation (Voltaren Emulgel†). There were no reports of serious adverse events in the gastro-intestinal (GI) tract, kidneys or liver from DI-EP. Mild GI symptoms and skin reactions occur in 2 and10% of patients, respectively. Conclusions: The patch delivery of DI in DI-EP affords controlled delivery of the active drug in contrast to that from application of gels or ointments of NSAIDs.Keywords
This publication has 65 references indexed in Scilit:
- Industrial Medicine and Acute Musculoskeletal Rehabilitation. 2. Medications for the Treatment of Acute Musculoskeletal PainArchives of Physical Medicine and Rehabilitation, 2007
- Aspirin and Related DrugsPublished by Taylor & Francis Ltd ,2004
- Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysisBMC Musculoskeletal Disorders, 2004
- Inhibitors of EicosanoidsPublished by Wiley ,2004
- Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic painBMJ, 2004
- Transdermal Approaches to Pain in Sports Injury ManagementOptometry and Vision Science, 2003
- Topical Nonsteroidal Anti-Inflammatory Therapy in OphthalmologyOphthalmologica, 2003
- Pharmacotherapy for regional musculoskeletal painBest Practice & Research Clinical Rheumatology, 2003
- Pharmacological Management of Neuropathic PainCNS Drugs, 2003
- Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control studyBMJ, 1995